Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.50 |
| ▸ | RELA | Q04206 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28387423 | 1.00 | MAPT (0.50) | MAPTRAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL361951 | 0.98 | MAPT (0.51) | MAPTRAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL27608353 | 0.84 | MAPT (0.51) | MAPTRAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL27669282 | 0.84 | AKR1C3 (0.56) | MAPTRAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL1497440 | 0.84 | AKR1C3 (0.56) | MAPTRAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL211298 | 0.84 | AKR1C3 (0.56) | MAPTRAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL6438925 | 0.83 | FBP1 (0.52) | MAPTRAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL18264401 | 0.82 | AKR1C3 (0.59) | MAPTRAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL11007893 | 0.82 | AKR1C3 (0.59) | MAPTRAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL6064620 | 0.82 | AKR1C3 (0.59) | MAPTRAB9ASMN1; SMN2NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802903-B2 | Process for preparing antiviral compound | ABBVIE INC. (US) | 2017-10-31 | — | — | US | claimed |
| EP-2593439-B1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2016-08-17 | — | — | EP | claimed |
| US-20160060228-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES | 2016-03-03 | — | — | US | claimed |
| US-9216952-B2 | Process for preparing antiviral compound | ABBVIE INC. (US) | 2015-12-22 | — | — | US | claimed |
| EP-2411372-B1 | PROCESS FOR PREPARING AN ANTIVIRAL COMPOUND | ABBVIE BAHAMAS LTD (BS) | 2014-07-23 | — | — | EP | claimed |
| EP-2593439-A2 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-05-22 | — | — | EP | claimed |
| EP-2411372-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | claimed |
| WO-2012009699-A2 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | WO | claimed |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | claimed |
| US-20110237793-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | claimed |
| WO-2010111348-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | claimed |
| EP-3415504-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2018-12-19 | — | — | EP | disclosed |
| EP-3056486-B1 | PROCESS FOR PREPARING INTERMEDIATES FOR ANTIVIRAL COMPOUNDS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-07-11 | — | — | EP | disclosed |
| US-9802903-B2 | Process for preparing antiviral compound | ABBVIE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-2593439-B1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2016-08-17 | — | — | EP | disclosed |
| EP-2411372-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2012009699-A2 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110237793-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2010111348-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237793-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ZC3HAV1, HAVCR2, MAVS | MAPT 3779/4885RAB9A 756/4885SMN1; SMN2 3493/4885 |
| US-20160060228-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ZC3HAV1, HAVCR2, MAVS | MAPT 3779/4885RAB9A 756/4885SMN1; SMN2 3493/4885 |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, MAVS, RNASE1 | MAPT 4108/4885RAB9A 771/4885SMN1; SMN2 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.